Codis

Executive Summary

Codis is a global Contract Development and Manufacturing Organization (CDMO) formed through the integration of legacy assets, focusing on commercial-scale spray drying, amorphous solid dispersions (ASD), and particle engineering. The company addresses critical bioavailability and manufacturing challenges for pharmaceutical, consumer health, OTC, and nutraceutical clients, operating large-scale GMP facilities in the US and UK. With decades of regulatory expertise and a specialized technology platform, Codis is well-positioned to capture growing demand for advanced drug delivery solutions, particularly for poorly soluble compounds. Its integrated service model and established infrastructure provide a competitive moat in the fragmented CDMO market. As the pharmaceutical industry increasingly adopts ASD and spray drying to enhance drug solubility, Codis benefits from first-mover advantages and high barriers to entry. The company's strategic focus on complex formulations and its ability to scale from development to commercial production make it a critical partner for innovators. While financial details remain undisclosed due to its private status, the trend toward outsourcing and the rising complexity of drug pipelines bode well for Codis's growth trajectory. However, competition from larger CDMOs and capital-intensive nature of the business pose ongoing risks.

Upcoming Catalysts (preview)

• Q4 2026Announcement of new capacity expansion or facility upgrade40% success
• Q2 2027Strategic partnership or multi-year supply agreement with a top pharma30% success
• Q1 2027Regulatory approval for a new ASD-based drug manufactured by Codis25% success